生活质量量表(FACT-EGFRI-18)在表皮生长因子受体抑制剂引起皮肤不良反应患者中的应用  

Research on the application of quality of life scale for epidermal growth factor receptor inhibitor related skin adverse reactions

作　　者：刘青[1] 彭艳梅[2] 张静怡 申文[3] 张旭[3] 孙晨耀 崔慧娟[1] LIU Qing;Peng Yan-mei;ZHANG Jing-yi

机构地区：[1]中日友好医院中西医结合肿瘤内科,北京100029 [2]北京中医药大学房山医院肿瘤科,北京102400 [3]北京中医药大学,北京100026

出　　处：《中日友好医院学报》2020年第5期263-266,270,共5页Journal of China-Japan Friendship Hospital

基　　金：中日友好医院院级课题(2016-2-QN-16)。

摘　　要：目的:评价中文版癌症治疗功能评价-表皮生长因子受体抑制剂-18量表(FACT-EGFRI-18)临床应用的信度、效度和可行性。方法:采用中文版FACT-EGFRI-18,根据纳入、排除标准选择表皮生长因子受体抑制剂(EGFRIs)相关皮肤不良反应的患者,进行问卷调查,收集问卷后对量表的信度、效度和可行性进行评价。结果:对42例2017年1月~2018年5月在中日友好医院就诊的患有EGFRIs相关皮肤不良反应的患者进行了问卷调查。该量表总Cronbachα系数为0.867,各维度的Cronbachα系数为0.673~0.900。患者的皮肤不良反应严重程度分级与FACT-EGFRI-18生活质量评分正相关,差异有统计学意义。探索性因子分析共提取5个公因子,累积贡献度为73.398%。量表回收率100%,患者易接受,可行性较好。结论:中文版FACT-EGFRI-18在临床中的应用信度、效度和可行性较好,是评价有EGFRIs相关皮肤不良反应患者生活质量的可靠工具。Objective:To evaluate the reliability,validity and feasibility of Chinese version of the cancer therapeutic function evaluation-epithelial growth factor receptor inhibitor scale 18(FACT-EGFRI-18)in clinical applications.Methods:The Chinese version of FACT-EGFRI-18 was used to conduct a questionnaire survey on patients with EGFRIs-related skin adverse reactions according to the inclusion and exclusion criteria.The reliability,validity and feasibility of the scale were evaluated after collecting the questionnaires.Results:A total of42 patients were included in this study.The total Cronbachαcoefficient of the scale was 0.867,and the Cronbachαcoefficient of each dimension was between 0.673 and 0.900.There was a positive correlation between the severity of CTCAE skin adverse reactions and FACT-EGFRI-18 quality of life assessment,and the difference was statistically significant.Exploratory factor analysis extracted a total of 5 common factors,with a cumulative contribution of 73.398%.The recovery rate of the scale was 100%,which was easier for patients to receive and has better feasibility.Conclusion:The Chinese version of FACT-EGFRI-18 has good reliability,validity and feasibility.It can be used to evaluate the quality of life of patients with EGFRIs-related skin adverse reactions.

关 键 词：表皮生长因子受体抑制剂 癌症治疗功能评价-表皮生长因子受体抑制剂-18量表 信度 效度 

分 类 号：R730.9[医药卫生—肿瘤]